scholarly journals Awareness regarding cardiac rehabilitation among patients with coronary heart disease attending a cardiac care centre, Kathmandu valley

2019 ◽  
Vol 16 (1) ◽  
pp. 47-50
Author(s):  
Rosy Shrestha ◽  
Sajeeb Shrestha
Keyword(s):  
Quality Of Life ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiac Rehabilitation ◽  
Cardiac Care ◽  
Care Centre ◽  
Duration Of Treatment ◽  
Cross Sectional ◽  
Low Middle Income Countries

Introduction: Coronary heart disease (CHD) is gradually emerging as a leading cause of morbidity and mortality of many low middle income countries like Nepal. Cardiac rehabilitation awareness program has been proved to be effective for reducing the mortality as well as improving the quality of life among CHD patients. The aim of this study was to explore the awareness on cardiac rehabilitation (CR) in patients with CHD attending a cardiac care centre, Nepal. Method: A descriptive cross sectional study design was used to examine 100 CHD patients attending out-patient departments of Shahid Gangalal National Heart Centre (SGNHC), Kathmandu, Nepal. Purposive sampling technique was used for data collection by face to face interview technique with self developed tool. Data was analyzed with descriptive and inferential statistics. Results: Of all 100 respondents, 55.0% were male and the mean age was 53.23±14.22 years. The median score of awareness was 17 with interquartile range (IQR) 14.0-19.75 and majority (57.0%) of respondents were unaware about CR. The awareness regarding CR was found highest in awareness regarding CHD (75.0%) whereas lowest score was found in time and duration needed for exercise per week (14.0%). The significant influencing variables were age, education status, duration of treatment and participation in CR program for CHD patients. Conclusion: The awareness on CR program in CHD patients in Nepal is not optimal, especially among 54 and above age group, illiterate people, those receiving treatment equal & more than 1 year duration and the CHD patients who didn’t get chance to participate on awareness programs. Hence, it is strongly recommended that health professionals including nurses should organize and promote CR programs including counseling session to improve the awareness level and ultimately enhance quality of life of CHD patients. 

scholarly journals Detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): A cross-sectional study

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243800
Author(s):  
Samia Peltzer ◽  
Hendrik Müller ◽  
Ursula Köstler ◽  
Frank Schulz-Nieswandt ◽  
Frank Jessen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Mental Disorders ◽  
Detection Rate ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Medication Therapy

Mental disorders (MD) are associated with an increased risk of developing coronary heart disease (CHD) and with higher CHD-related morbidity and mortality. There is a strong recommendation to routinely screen CHD patients for MDs, diagnosis, and treatment by recent guidelines. The current study aimed at mapping CHD patients' (1) state of diagnostics and, if necessary, treatment of MDs, (2) trajectories and detection rate in healthcare, and (3) the influence of MDs and its management on quality of life and patient satisfaction. The design was a cross-sectional study in three settings (two hospitals, two rehabilitation clinics, three cardiology practices). CHD patients were screened for MDs with the Hospital Anxiety and Depression Scale (HADS), and, if screened-positive, examined for MDs with the Structured Clinical Interview for DSM-IV (SCID-I). Quality of Life (EQ-5D), Patient Assessment of Care for Chronic Conditions (PACIC), and previous routine diagnostics and treatment for MDs were examined. Descriptive statistics, Chi-squared tests, and ANOVA were used for analyses. Analyses of the data of 364 patients resulted in 33.8% positive HADS-screenings and 28.0% SCID-I diagnoses. The detection rate of correctly pre-diagnosed MDs was 49.0%. Physicians actively approached approximately thirty percent of patients on MDs; however, only 6.6% of patients underwent psychotherapy and 4.1% medication therapy through psychotherapists/psychiatrists. MD patients scored significantly lower on EQ-5D and the PACIC. The state of diagnostic and treatment of comorbid MDs in patients with CHD is insufficient. Patients showed a positive attitude towards addressing MDs and were satisfied with medical treatment, but less with MD-related advice. Physicians in secondary care need more training inadequately addressing mental comorbidity.

scholarly journals Health-Related Quality of Life in Patients With Coronary Heart Disease After Residential vs Ambulatory Cardiac Rehabilitation

2009 ◽  
Vol 73 (3) ◽  
pp. 476-483 ◽  
Author(s):  
Anna Jegier ◽  
Anna Jegier ◽  
Katarzyna Szmigielska ◽  
Maria Bilinska ◽  
Lechoslaw Brodowski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiac Rehabilitation ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Ambulatory Cardiac Rehabilitation

scholarly journals Economic evaluation protocol for a multicentre randomised controlled trial to compare Smartphone Cardiac Rehabilitation, Assisted self-Management (SCRAM) versus usual care cardiac rehabilitation among people with coronary heart disease

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e038178
Author(s):  
Lan Gao ◽  
Ralph Maddison ◽  
Jonathan Rawstorn ◽  
Kylie Ball ◽  
Brian Oldenburg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Economic Evaluation ◽  
Cardiac Rehabilitation ◽  
Controlled Trial ◽  
Productivity Loss ◽  
Self Management ◽  
Randomised Controlled

IntroductionIt is important to ascertain the cost-effectiveness of alternative services to traditional cardiac rehabilitation while the economic credentials of the Smartphone Cardiac Rehabilitation, Assisted self-Management (SCRAM) programme among people with coronary heart disease (CHD) are unknown. This economic protocol outlines the methods for undertaking a trial-based economic evaluation of SCRAM in the real-world setting in Australia.Methods and analysisThe within-trial economic evaluation will be undertaken alongside a randomised controlled trial (RCT) designed to determine the effectiveness of SCRAM in comparison with the usual care cardiac rehabilitation (UC) alone in people with CHD. Pathway analysis will be performed to identify all the costs related to the delivery of SCRAM and UC. Both a healthcare system and a limited societal perspective will be adopted to gauge all costs associated with health resource utilisation and productivity loss. Healthcare resource use over the 6-month participation period will be extracted from administrative databases (ie, Pharmaceutical Benefits Scheme and Medical Benefits Schedule). Productivity loss will be measured by absenteeism from work (valued by human capital approach). The primary outcomes for the economic evaluation are maximal oxygen uptake (VO2max, mL/kg/min, primary RCT outcome) and quality-adjusted life years estimated from health-related quality of life as assessed by the Assessment of Quality of Life-8D instrument. The incremental cost-effectiveness ratio will be calculated using the differences in costs and benefits (ie, primary and secondary outcomes) between the two randomised groups from both perspectives with no discounting. All costs will be valued in Australian dollars for year 2020.Ethics and disseminationThe study protocol has been approved under Australia’s National Mutual Acceptance agreement by the Melbourne Health Human Research Ethics Committee (HREC/18/MH/119). It is anticipated that SCRAM is a cost-effective cardiac telerehabilitation programme for people with CHD from both a healthcare and a limited societal perspective in Australia. The evaluation will provide evidence to underpin national scale-up of the programme to a wider population. The results of the economic analysis will be submitted for publication in a peer-reviewed journal.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN12618001458224).

Sign in / Sign up

Export Citation Format

Share Document